VJOncology Podcast

Latest Episodes:

The Lung Cancer Sessions: Updates from WCLC 2022 Sep 02, 2022

Show notes

The Lung Cancer Sessions from VJOncology aim to provide interesting perspectives from leading experts on the big topics in lung cancer research.

In this podcast, we hear from Lizza Hendriks of Maastricht University and Tiziana Vavala of the University of Turin as they discuss key updates from the IASLC World Congress on Lung Cancer in Vienna, Austria. Topics include the use of sotorasib in KRASG12C-mutant non-small cell lung cancer, oligometastatic disease, and key trial updates from the meeting.

The post The Lung Cancer Sessions: Updates from WCLC 2022 appeared first on VJOncology.

TILs, Cancer Vaccines & the Future of Cellular Therapies in Melanoma with Allison Betof Warner Aug 26, 2022

Show notes

Immunotherapy plays a vital role in the management of patients with advanced-stage melanoma, and more recently, adoptive cell therapies and cancer vaccines have shown to be viable, novel treatment approaches able to induce complete and durable remissions in patients with melanoma.

In this exclusive podcast, VJOncology speaks to Allison Betof Warner, MD, PhD, from Memorial Sloan Kettering Cancer Center, New York, NY, who discusses the clinical potential of cellular therapies in the management of patients with melanoma, including the use of tumor-infiltrating lymphocyte (TIL) therapies as well as cancer vaccines and the next steps for these novel therapeutic approaches.

The post TILs, Cancer Vaccines & the Future of Cellular Therapies in Melanoma with Allison Betof Warner appeared first on VJOncology.

Updates in lung cancer from WCLC 2022 Aug 19, 2022

Show notes

The International Association for the Study of Lung Cancer (IASLC) held their World Congress in Lung Cancer (WCLC) in Vienna, Austria, on the 6-9^th August 2022. The congress brought together leading experts in lung cancer from around the world, to hear practice-changing trial updates and discuss the best ways to improve care for patients.

In this podcast, we hear from Dr Rachel Murray of Leeds Cancer Centre, UK, on the Yorkshire Enhanced Stop Smoking (YESS) study, and Professor Sanjay Popat from the Royal Marsden NHS Foundation Trust, UK, on the Phase III CALGB140503 trial. Professor Martin Reck, from the Lung Clinic Grosshansdorf, Germany, gave us an overview of some of the key trials presented at the congress, including JAVELIN, PRIMUS, NintNivo, IMpower010, and NADIM, and Dr David Baldwin of Nottingham University Hospitals NHS Trust, UK, talks on the impact of COVID-19 on lung cancer care and how the effects can be mitigated.

The post Updates in lung cancer from WCLC 2022 appeared first on VJOncology.

Updates in Checkpoint Inhibitors for Kidney Cancer Aug 12, 2022

Show notes

The advent of immune checkpoint inhibitors as a distinct class of immunotherapy has made a large impact within the field of oncology, providing a form of treatment that utilizes the host immune system to target the cancer. Immune checkpoint inhibitors regulate the immune system and prevent autoimmunity, with cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death receptor-1 ligand (PD-L1) being common targets for checkpoint inhibitors. Ipilimumab was the first FDA-approves checkpoint inhibitor and was indicated for patients with melanoma. Pembrolizumab and nivolumab, both PD-1 inhibitors, have been approved for renal cell carcinoma (RCC) and multiple clinical trials have demonstrated the potential of novel combination strategies.

In this special podcast, leading genitourinary cancer experts Yousef Zakharia, MD, University of Iowa, Iowa City, IA, Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, discuss pivotal clinical trial data assessing pembrolizumab and nivolumab in clear-cell RCC as well as immune-related adverse events observed in patients receiving immune checkpoint inhibition therapy.

The post Updates in Checkpoint Inhibitors for Kidney Cancer appeared first on VJOncology.

iwCART Sessions: CAR-T clinical advances in breast and ovarian cancer Aug 05, 2022

Show notes

The International Workshop on CAR-T (iwCAR-T) 2022 featured many updates on the development of CAR-T therapies for the treatment of solid tumors. In this podcast, we hear from Jose Conejo-Garcia of Moffitt Cancer Center, Tampa, FL, and Jennifer Specht of Fred Hutchinson Cancer Research Center and the University of Washington, in Seattle, WA, as they discuss the latest CAR-T updates in breast cancer and ovarian cancer.

The post iwCART Sessions: CAR-T clinical advances in breast and ovarian cancer appeared first on VJOncology.

Clinical Applications of ctDNA in Oncology Jul 29, 2022

Show notes

Circulating tumor DNA (ctDNA) are small fragments of nucleic acid that are released into the circulating system via multiple mechanisms including apoptosis and necrosis, thereby reflecting the genomic landscape of the tumor from which it was derived. Due to its short half-life, ctDNA can facilitate in tracking the tumor burden in real-time, offering a valuable minimally invasive opportunity to monitor disease in individual cancer patients. Although not yet implemented in clinical practice, ctDNA has demonstrated potential clinical applications across all stages of cancer management, including in early diagnosis, identification of targetable genetic alterations, monitoring response to treatment and detection of minimal residual disease. Indeed, several studies have shown ctDNA to predict relapse significantly earlier than conventional clinical methods, thereby holding the potential to improve patient prognosis and survival outcomes.

In this podcast, we spoke with Jeanne Tie, MBChB, FRACP, MD, Peter MacCallum Cancer Centre, Sanjay Popat, PhD, MBBS, FRCP, The Royal Marsden NHS Foundation Trust, London, UK, Miguel Garcia-Pardo, MD, Princess Margaret Cancer Center, Toronto, Canada, and Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, who provide an overview of the applications of ctDNA in clinical practice and the remaining challenges yet to be overcome prior to its implementation in clinical practice.

The post Clinical Applications of ctDNA in Oncology appeared first on VJOncology.

iwCART Sessions: CAR-T clinical advances in lung cancer Jul 22, 2022

Show notes

The International Workshop on CAR-T (iwCAR-T) 2022 featured many updates on the development of CAR T-cell therapies for the treatment of solid tumors. This roundtable discussion on the development of cellular therapies in lung cancer was chaired by Melissa Johnson, MD from the Sarah Canon Research Institute and Tennessee Oncology, Nashville, TN, and featured Sandip Patel, MD,UC San Diego Health, San Diego, CA, Sylvia Lee, MD,Fred Hutchinson Cancer Research Center, Seattle, WA, and Prasad Adusumilli, MD, FACS, Memorial Sloan Kettering Cancer Center, New York, NY.

In this session, alterations to the composition of the tumor microenvironment as a result of immune checkpoint therapy and the implications of this, as well as tumor-infiltrating lymphocyte (TIL) therapy for the treatment of solid tumours are discussed. This discussion was filmed during the International Workshop on CAR-t (iwCAR-T) held in Tampa, FL.

The post iwCART Sessions: CAR-T clinical advances in lung cancer appeared first on VJOncology.

ASCO 2022: Updates in Gastrointestinal Cancer Jul 15, 2022

Show notes

The American Society of Clinical Oncology Annual Meeting 2022 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer.

In this podcast, we hear from some of the leading experts in gastrointestinal cancer, as they discuss the biggest trials and hot topics from the meeting. For pancreatic cancer, we heard from Dr Vinod Balachandran about mRNA neoantigen vaccines and Prof. Rainer Fietkau about the CONKO-007 trial. Dr Ian Chau discussed the role of CAR T-cell therapies in the treatment of gastric cancer and gave us an update on CheckMate-648. For colorectal cancer, we heard from Dr Christine Parseghian about anti-EGFR rechallenge therapy, Dr Richard Kim about the KEYNOTE-651 trial, Prof. Jean-Pierre Gerard about the OPERA trial, and Prof. Chiara Cremolini and Dr Takayuki Yoshino the results and impact of the PARADIGM trial.

The post ASCO 2022: Updates in Gastrointestinal Cancer appeared first on VJOncology.

ASCO 2022: Updates in Genitourinary Cancer Jul 08, 2022

Show notes

In this podcast, we hear from some of the leading experts in genitourinary cancer, as they discuss the biggest trials and hot topics from the meeting. For prostate cancer, we hear from Prof. Arun Azad who explains the evolution of standard of care for patients with metastatic hormone-sensitive prostate cancer, Prof. Andrew Armstrong who gives us an update on the ARCHES trial, Dr Anis Hamid who discusses the use of circulating tumor cells in prostate cancer, Dr Clara Hwang who discusses how to overcome racial disparities in prostate cancer treatment, and Prof. Scott Tagawa and Dr Andrei Gafita discuss the use of PSMA-targeted radioligand therapies for prostate cancer, including updates from the VISION trial. For kidney cancer, we caught up with Dr Pavlos Msaouel about the results of a Phase I/II trial of sitravatinib and nivolumab in patients with clear cell renal cell carcinoma, as well as the key unmet needs in kidney cancer. Finally, for bladder cancer, we heard from Dr Joaquim Bellmunt about the latest updates from JAVELIN Bladder100 and Prof. Rob Jones about results from the cabozantinib arm of the ATLANTIS trial.

The post ASCO 2022: Updates in Genitourinary Cancer appeared first on VJOncology.

ASCO 2022: Updates in Breast Cancer Jul 01, 2022

Show notes

In this podcast, we hear from some of the leading experts in breast cancer, as they discuss the biggest trials and hot topics from the meeting. Dr Kevin Kalinsky gives an overview of the MAINTAIN and postMONARCHE trials, Prof. Lajos Pusztai discusses the KEYNOTE-522 trial, and Dr Erika Hamilton updates us on the DESTINY-Breast03 trial. We also hear from Dr Hamilton and Dr Hope Rugo on the practice-changing DESTINY-Breast04 results.

The post ASCO 2022: Updates in Breast Cancer appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected